Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

Phase 3 Unknown 300 enrolled Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products

RandomizedParallel-groupDouble-blindPrevention

Summary

Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI "Chumakov FSC R\&D IBP RAS", of childrens aged 12-17" (Clinical trials, phase III). Study purpose is to assess the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified coronavirus vaccine of chidrens aged 12-17

Timeline

Start: 2022-04-01
Primary completion: 2023-12-01
Completion: 2024-02-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CoviVac	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.